ABSTRACT
I]TID labeling of M2-9 and M2-13 without changing the relative 125 I incorporation at these positions, whereas PCP and HTX each altered the pattern of [ 125 I ]TID incorporation at M2-9 and M2-13. These results indicate that tetracaine and TID bind in a mutually exclusive manner to a common site in the closed channel that is spatially separated from the binding sites for PCP and HTX.
The nicotinic acetylcholine receptor (nAChR) of vertebrate skeletal muscle and Torpedo species electric organ is a well characterized ligand-gated ion channel that exists in at least three interconvertible conformations: the resting (closed channel) state, the open channel state, and the agonist bound, nonconducting desensitized state (Hucho et al., 1996; Corringer et al., 2000) . The nAChR is a pentamer of four homologous subunits (␣ 2 ␤␥␦) with each subunit containing four hydrophobic transmembrane segments (M1-M4). The M2 segments of each subunit are ␣-helical and associate at the central axis of the nAChR to form the ion channel (Hucho et al., 1986; Imoto et al., 1988; Charnet et al., 1990; Revah et al., 1990; Imoto et al., 1991) , with additional contributions from N-terminal residues of the M1 segments (Zhang and Karlin, 1997) . The M3 and M4 segments contribute to the lipid-protein interface (Blanton and Cohen, 1994) .
Many positively charged noncompetitive antagonists (NCAs), compounds that inhibit nAChR function by binding to sites other than the agonist binding site, bind within the lumen of the ion channel (for review, see Arias, 1998) . Mutations in M2 affect the potencies of aromatic amine NCAs, including QX-222 (Charnet et al., 1990) and phencyclidine (Eaton et al., 2000) , whereas mutations in M1 affect quinacrine potency (Tamamizu et al., 1995) . For Torpedo species nAChRs equilibrated with agonist (i.e., in the desensitized state), the NCAs [ 3 H]chlorpromazine and [ 3 H]triphenylmethylphosphonium photoaffinity-labeled residues toward the N-terminal (cytoplasmic) end of each M2 segment (residues M2-6 and M2-9, with reference to the conserved Lys at the N-terminal end of each M2 segment) (Giraudat et al., 1986 (Giraudat et al., , 1987 (Giraudat et al., , 1989 Hucho et al., 1986; Revah et al., 1990) , whereas [ 3 H]meproadifen mustard reacted with ␣Glu-262 (M2-20) at the extracellular end (Pedersen et al., 1992) . In the absence of agonist (i.e., in the closed channel state), [ 3 H]tetracaine was specifically photoincorporated into amino acids in the middle of each M2 segment (M2-9 and M2-13) (Gallagher and Cohen, 1999 (DiPaola et al., 1990) . Affinity labeling studies also have shown that uncharged NCAs bind within the nAChR ion channel. In the absence of agonist, [ 125 I] 3-(trifluoromethyl)-3-(m-iodophenyl)diazirine (TID) specifically labeled the same amino acids as [ 3 H]tetracaine (M2-9 and -13 of each subunit), whereas in the desensitized state [
125 I]TID labeled residues deeper in the pore (M2-2 and -6) (White and Cohen, 1992) . In the absence of agonist, [ 3 H]diazofluorene selectively labeled amino acids in ␦-subunit (␦M2-9 and -13) and in the ␤-subunit (␤M2-13), with the labeling in the desensitized state also shifted to residues closer to the cytoplasmic end (␦M2-6, ␤M2-9 and -10) (Blanton et al., 1998 (Heidmann et al., 1983 They serve as useful probes of the NCA site in the nAChR because they bind relatively weakly to the ACh sites, and they seem to interact with fewer low-affinity sites in the Torpedo species nicotinic postsynaptic membrane than other, more lipophilic NCAs. Although these compounds are assumed to bind within the ion channel, the binding site for neither NCA has been directly identified by affinity labeling. HTX and PCP bind in a mutually exclusive manner with each other and with other aromatic amine NCAs. In the desensitized state, PCP and HTX bind competitively with [ 3 H]meproadifen mustard , a compound that seems to bind at the extracellular end of the ion channel domain (M2-20), and also with [ 3 H]chorpromazine (Heidmann et al., 1983) , a compound that binds lower in the channel domain (M2-6 and -9). In the absence of agonist, PCP and HTX bind competitively with [ 3 H]tetracaine (Middleton et al., 1999) , a result suggesting that the three ligands bind in a mutually exclusive manner to a common site at M2-9 and M2-13. However, in the absence of agonist, PCP and HTX interact allosterically with TID, a compound that binds to the same site as [ 3 H]tetracaine. When evaluated at the level of nAChR subunits, PCP binding to its high-affinity site inhibited specific [ 125 I]TID photoincorporation in the ␣-, ␤-, and ␥-subunits by only 20 to 30%, whereas it increased labeling in the ␦-subunit (White and Cohen, 1988; Ryan et al., 2001 
Experimental Procedures
Materials. nAChR-rich membranes were isolated from electric organs of Torpedo species (Winkler Enterprises, San Pedro, CA) as described elsewhere (Pedersen et al., 1986 3 H]tetracaine (48 Ci/mmol) was prepared by tritium reduction (PerkinElmer Life Science Products, Boston, MA) of 3,5-dibromotetracaine as described previously (Gallagher and Cohen, 1999) . PCP was from Applied Science (State College, PA) and HTX was kindly provided by Dr. Y. Kishi (Harvard University, Cambridge, MA). Nonradioactive TID was a gift from Dr. S. Husain (Massachusetts General Hospital, Boston, MA) and was repurified by silica gel chromatography (100% hexane elution) and stored in 100% ethanol after the hexane was removed by rotary evaporation. Purity and concentration of the TID was assessed by silica thin-layer chromatography and UV absorption at 365 nm (Brunner and Semenza, 1981) . Structures of the drugs are shown in Fig. 1 . ]tetracaine (10 nM) to nAChR-rich membranes in Torpedo species physiological saline (250 mM NaCl, 5 mM KCl, 3 mM CaCl 2 , 2 mM MgCl 2 , 5 mM NaPi, pH 7.0) was measured by a filtration assay (Middleton et al., 1999 ]TID incorporation in the gel was detected by autoradiography or by use of a Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA). The nAChR ␥-subunit 125 I incorporation was quantified using the ImageQuaNT software, with background levels calculated locally.
Preparative [ 125 I]TID photolabeling was performed essentially as described previously (White and Cohen, 1992; Blanton and Cohen, 1994) . nAChR-rich membranes (5-7 mg at 2 mg of protein/ml in Torpedo species physiological saline) were equilibrated for 30 min with 6.5 M [
125 I]TID and in the absence or presence of an amine NCA and then photolyzed at 365 nm under one of two conditions. The samples were either photolyzed for 30 min in open glass containers at a distance of 6 cm (White and Cohen, 1992) or irradiated in closed glass vials for 10 min at a distance of 1 cm (Blanton and Cohen, 1994) . Because the closed vials more effectively contained volatilized [ 125 I]TID and because the pattern of [
125 I]TID labeling within the nAChR M2 segments did not vary between the two methods, the closed vial method was used routinely.
To facilitate the isolation of subunits and proteolytic fragments, the [
125 I]TID-labeled membranes were further photolabeled with the fluorescent, hydrophobic probe 1-azidopyrene (1-AP) as described previously (Blanton and Cohen, 1994 ). The membrane suspensions were then pelleted, resuspended in sample buffer, and electrophoresed on 1.5-mm thick slab gels.
After electrophoresis, the unstained gels were illuminated on a 365-nm UV light box and the nAChR subunits were visualized by 1-AP fluorescence. The bands containing the nAChR ␤-, ␥-, and ␦-subunits were excised from the gels, diced, and eluted in 10 ml of elution buffer (0.1 M NH 4 HCO 3 /0.1% SDS, pH 7.8), whereas the ␣-subunit was subjected to an "in-gel" S. aureus glutamyl endopeptidase (V8 protease) digestion (Cleveland et al., 1977; Pedersen et al., 1986) . The ␣-subunit fragment of ϳ20 kDa (␣V8-20) was visualized by 1-AP fluorescence (Blanton and Cohen, 1992) , excised from the gel, and eluted as described above.
After 4 days of elution, the samples were concentrated in Centriprep-10 (␣V8-20) or Centriprep-30 (␤-,␥-, and ␦-subunits) Microconcentrators (Amicon, Beverly, MA) to approximately 400 l and precipitated in 1.6 ml of acetone at Ϫ20°C to remove excess SDS. The ␣V8-20 fragments and ␦-subunits were resuspended in 125 l of 15 mM Tris, pH 8.1/0.1% SDS, and the ␤-subunits were resuspended in 150 l of 0.1 M NH 4 HCO 3 , pH 7.8/0.5% Genapol/0.02% SDS. Protein concentrations of the samples were measured using a bicinchoninic acid-based protein assay (Micro BCA Protein Assay; Pierce), and the amount of [
125 I]TID incorporation into each subunit was determined by gamma counting.
Proteolytic Digestion and Fragment Purification. The goal in these experiments was to characterize the effect of noncompetitive antagonists on [
125 I]TID incorporation into the M2 hydrophobic segments. Therefore, the techniques used to generate the [ 125 I]TIDlabeled fragments used the digestion conditions previously optimized (White and Cohen, 1992; Gallagher and Cohen, 1999) to produce fragments beginning at the N termini of the M2 segments. Briefly, solutions (1 mg of protein/ml) of ␣V8-20 fragments and intact ␦-subunit in 15 mM Tris, pH 8.1, 0.1% SDS were digested for 3 to 5 days with 4 U/ml of EndoLys-C, whereas the ␤-subunit (approximately 1 mg/ml) in 100 mM NH 4 HCO 3 , pH 7.8/0.02% SDS/0.5% Genapol C-100 was digested with trypsin [3:2 (w/w), protein/trypsin] for 3 to 7 days. The ␣V8-20 and ␦-subunit digests were fractionated on 16.5% T/3% C Tricine gels (Schagger and von Jagow, 1987) , and the ␤-subunit digests were resolved on a 16.5%T/6%C Tricine gel to obtain higher resolution. Regions of the gels that were expected to contain peptides beginning at the N termini of the M2 segments were identified based upon the migration of prestained molecular mass markers and the pattern of 1-AP fluorescence (Gallagher and Cohen, 1999) . Nonfluorescent regions at 8 and 7 kDa were excised from the ␣V8-20 and ␤-subunit digests, respectively, and a fluorescent band at 10 kDa was excised from the ␦-subunit digest. Material was eluted from the bands, and the eluates were concentrated to 0.3 ml in Centricon-3 microconcentrators (Amicon). The concentrates were then fractionated by reversed phase HPLC as a second purification step that also removed the majority of the SDS. Based upon the distribution of 125 I, fractions were pooled, dried by vacuum centrifugation, and then resuspended in 25 l of 100 mM NH 4 HCO 3 /0.05% SDS.
Sequence Analysis. The purified samples were applied to chemically modified glass fiber filters (Beckman, Palo Alto, CA) that were first washed with distilled water and methanol to remove impurities that inhibit binding of hydrophobic peptides. The purified peptides were fixed to the filters by delivery of gas trifluoroacetic acid for 4 min and then the SDS was removed from the filters by washing them for 5 min with ethyl acetate. The peptides were sequenced on an ABI 477 protein sequencer (Applied Biosystems, Foster City, CA) with gas phase sequencing cycles. During Edman degradation, two thirds of each sample was sent to a fraction collector for 125 I gamma counting and one third was injected on an amino acid analyzer (ABI 120A) to identify the PTH-amino acid. Picomoles of each PTH amino acid were calculated from the peak height on the analyzer chromatogram (ABI 610A Data Analysis Program version 1.2.1). The backgroundsubtracted yields (excluding serines and cysteines) of each sequencing cycle were fit to the equation I(n) ϭ I 0 ϫ R n , where I(n) is picomoles of PTH amino acid at cycle n, I 0 is the initial peptide quantity in picomoles, and R is the sequencer repetitive yield. The efficiency of [
125 I]TID incorporation into residue n, expressed as cpm n per picomole (I n ), was calculated by [cpm n Ϫ cpm n Ϫ 1 ]/2 ϫ I n with the factor of 2 in the denominator because at each cycle the volume counted was twice the volume injected into the amino acid analyzer. We employed a single factor ANOVA test (Microsoft Excel) to determine whether tetracaine, PCP, or HTX induced significant differences in the percentage of change of [ 125 I]TID labeling efficiencies of ␣M2-9, ␣M2-13, ␦M2-9, and ␦M2-13. We also used a two-tailed t test (Microsoft Excel; Microsoft, Redmond, WA) to determine whether there were significant differences in the ratios of 125 I incorporation in M2-9 and M2-13 within a single subunit.
Results
In initial experiments, we examined the effects of tetracaine on the photoincorporation of [
125 I]TID into nAChR-rich membranes as well as the effects of TID on the reversible binding of [ (Fig. 2) . nAChR-rich membranes (1.5 M ACh sites) were equilibrated with 6.5 M [ 125 I]TID and various concentrations of tetracaine, and after photolysis the polypeptides were separated by SDS-PAGE. The gel was stained with Coomassie blue to allow identification of nAChR subunits and to verify that the lanes contained similar amounts of protein, and the distribution of 125 I was determined by PhosphorImaging (Fig. 2A) . Consistent with previous results (White and Cohen, 1988) , [ 125 I]TID was photoincorporated into each nAChR subunit, with the ␥-subunit labeled most efficiently. (A prominently labeled ␥-subunit fragment migrating near 45 kDa was also noted.) Tetracaine reduced 125 I incorporation in each nAChR subunit in a dosedependent manner, whereas it had no effect on the 125 I incorporation in the ␣-subunit of the Na ϩ /K ϩ -ATPase, which was labeled at lower efficiency than any of the nAChR subunits in the absence of tetracaine. When the concentration dependence of tetracaine inhibition of 125 I incorporation in nAChR ␥-subunit was quantified (Fig. 2B) , the data were fit by a single site model with an IC 50 value of 3 M, and tetracaine reduced subunit labeling by ϳ90%. The IC 50 value was the same as for its inhibition of [ 3 H]HTX binding and, as expected, for tetracaine binding to its high-affinity site in the nAChR M2 ion channel domain (Gallagher and Cohen, 1999; Middleton et al., 1999) . Nonradioactive TID also inhibited the reversible binding of [ 3 H]tetracaine (Fig. 2B ) with a concentration dependence characterized by an IC 50 value of 3 M. At high concentrations, TID inhibited at least 95% of specifically bound [
3 H]tetracaine. These results contrasted with the interactions between TID and PCP or HTX (White and Cohen, 1988; White et al., 1991 125 I]TID in the absence of additional ligand and in the presence of 30 M tetracaine, 50 M PCP, or 30 M HTX. The suspensions were photolyzed, and the nAChR ␤-, ␥-, and ␦-subunits as well as the ␣V8-20 fragment were isolated as described under Experimental Procedures. Typically, 100 to 200 g of each subunit or of ␣V8-20 were recovered. Based upon previous studies (Gallagher and Cohen, 1999) , digestion of ␣V8-20 or ␦-subunit with EndoLys-C would produce fragments of ϳ10 kDa beginning at the N termini of the M2 segments that can be purified by Tricine SDS-PAGE and HPLC. For the ␤-subunit, digestion with trypsin produces a similar fragment of ϳ7 kDa (White and Cohen, 1992) . For nAChRs labeled with [
125 I]TID in the absence or presence of amine NCAs, we also found that when aliquots of the subunit digests were fractionated by Tricine SDS-PAGE, for both ␣V8-20 and the ␦-subunit, the predominant [
125 I]TID-labeled fragments had mobilities of ϳ10 kDa (Fig. 3) . The presence of tetracaine or HTX, but not PCP, reduced 125 I incorporation in the ␣-and ␦-subunit fragments without the appearance of any novel labeled bands. Trypsin digestion of labeled ␤-subunit produced a specifically labeled band of ϳ7 kDa (data not shown). The bulk of these digests was fractionated by Tricine SDS-PAGE on a preparative scale, and the material eluted from the gel bands was further purified by reversed phase HPLC (Fig. 4) , from which the fractions containing the peak of 125 I were pooled for N-terminal sequence analysis. 125 I]TID in the absence and presence of 30 M tetracaine. Sequence analysis of the purified ␣-, ␤-, and ␦-subunit fragments each revealed a single sequence beginning at the N terminus of the M2 segments (Fig. 5) . For each of the subunit fragments isolated from nAChRs that were labeled in the absence of tetracaine, there was 125 I release at cycles 9 and 13 of Edman degradation, corresponding to incorporation at ␣Leu-251 (␣M2-9) and ␣Val-255 (␣M2-13), ␤Leu-257 (␤M2-9), and ␤Leu-261 (␤M2-13), or ␦Leu-265 (␦M2-9) and ␦Leu-269 (␦M2-13). These results agree with the previous characterizations of amino acids in the nAChR M2 domain that are specifically labeled by [ 125 I]TID (Blanton and Cohen, 1992; White and Cohen, 1992) . As was seen previously, within ␤-subunit [ 125 I]TID was incorporated with greater efficiency at ␤M2-9 than at ␤M2-13, whereas for ␣-and ␦-subunits, the labeling at M2-13 was more prominent. Sequence analysis of the fragments isolated from nAChRs labeled in the presence of tetracaine similarly were characterized by 125 I release in the M2 segments only at positions 9 and 13 (Fig. 5) , but for each subunit the efficiency of incorporation at M2-9 and M2-13 was reduced by 90% (Table 1A) . When the data were combined from multiple labeling experiments, tetracaine at 30 M reduced the efficiency of [ 125 I]TID labeling of ␣M2-9, ␣M2-13, ␤M2-9, ␤M2-13, ␦M2-9, and ␦M2-13 by 88 Ϯ 4% (Table 2 ). There was no significant difference in the relative reduction of labeling in any of the residues (ANOVA, p ϭ 0.76). Furthermore, there were no significant differences in the ratios of 125 I incorporation in ␦M2-9 to ␦M2-13 (p ϭ 0.77) or ␣M2-9 to ␣M2-13 (p ϭ 0.89) in ]TID-labeled ␣V8-20 and ␦-subunits and trypsin digests of labeled ␤-subunits were fractionated by Tricine SDS-PAGE. The bands of 8 to 10 kDa expected to contain fragments beginning at the N termini of M2 were excised and eluted as described under Experimental Procedures and then fractionated by reversed phase HPLC (Brownlee C-4 column, 0.2 ϫ 10 cm) with the elution gradient increasing linearly from 25% to 100% solvent B (60% acetonitrile, 40% isopropanol, 0.05% trifluoroacetic acid) in 80 min. (Solvent A was 0.08% trifluoroacetic acid.) Flow was 0.2 ml/min, fractions were collected every 2.5 min, and total 125 I cpm in each of the fractions was determined by gamma counting. Each of the profiles shown for a given subunit is from the same labeling experiment, but the data for the ␣-subunit are from different labeling experiment than the data for the ␤-and ␦-subunits. There was no labeling experiment in which the effect of tetracaine on [
125 I]TID-labeling in ␣-subunit was characterized at the same time as PCP and HTX, so for the ␣-subunit, no data are included for tetracaine. For the ␣-subunit, fractions 26 and 27 were pooled for sequence analysis, whereas for ␤-and ␦-subunits, fractions 28 to 31 and 25 to 26 were pooled. 125 I cpm recovered in the pooled fractions: ␣-subunit (A) (control, 63,900; ϩPCP, 40,000; ϩHTX, 13,300); ␤-subunit (B) (control, 5,650; ϩtetracaine, 2,120; ϩPCP, 2,190; ϩHTX, 3,440); ␦-subunit (C) (control, 26,090; ϩtetracaine, 4,540; ϩPCP, 33,600; ϩHTX, 7,500). ]TID in the absence of additional ligand and in the presence of either 50 M PCP or 30 M HTX. These concentrations of NCAs were chosen to maximize binding to the highaffinity site while avoiding binding to the agonist site or to other low-affinity binding sites (Heidmann et al., 1983) . At these concentrations, PCP and HTX each caused maximal change in of [
125 I]TID incorporation into the nAChR as determined at the level of individual subunits (White and Cohen, 1988) . The suspensions were photolyzed, and the nAChR ␤-, ␥-, and ␦-subunits as well as the ␣V8-20 fragment were isolated. HTX reduced 125 I incorporation in ␣V8-20 by 80%, ␤-subunit by 70%, ␥-subunit by 80%, and ␦-subunit by 50%. PCP reduced labeling in the ␤-subunit by 20% and in the ␣V8-20 fragment by 60%, but it increased labeling in the ␦-subunit by 20% and in the ␥-subunit by 10%. These results were generally consistent with previous studies (White and Cohen, 1988) . Fragments of the ␣-, ␤-, and ␦-subunits that begin at the N termini of the M2 segments were generated, purified, and sequenced (Figs. 6 and 7) . For the fragments isolated from nAChRs labeled in the presence of PCP (Fig. 6) or HTX (Fig. 7) there were peaks of 125 I release in cycles 9 and 13, without the appearance of any novel labeled amino acids within the M2 segments. In contrast to tetracaine, PCP altered 125 I incorporation into each residue differently ( Fig.  6 ; Table 1B ). The addition of 50 M PCP enhanced the labeling of ␦M2-9 by 2-fold while reducing incorporation by 30 to 70% at the equivalent position in ␣M2 and ␤M2. In the presence of PCP there was no change in the labeling of ␦M2-13. When the data were combined from multiple experiments (Table 2) (Fig. 7) , with the percentage reduction differing among the labeled residues: ␣M2-9 (93%), ␣M2-13 (94%), ␤M2-9 (54%), ␦M2-9 (67%), and ␦M2-13 (86%) ( Table 1C) . When the results from independent experiments were averaged ( ]TID incorporation at M2-9 and M2-13 in the absence of additional ligand (control) or in the presence of tetracaine, PCP, or HTX was calculated as described under Experimental Procedures. From the data for each labeling experiment the ratios of labeling at M2-9 and M2-13 were calculated, and the averages of the ratios were determined for all experiments. In addition, for each position the percentage of reduction of labeling was determined from the efficiency of [ molpharm.aspetjournals.org statistically significant difference in the alterations in labeling efficiencies (ANOVA p ϭ 0.14). Nonetheless, there were consistently larger reductions at ␦M2-13 than ␦M2-9. Consequently, HTX caused statistically significantly changes in the ratios of incorporation in M2-9 to M2-13 in the ␦-subunit (0.51, ϪHTX; 1.1, ϩHTX, p Յ 0.001). There was no significant change in the ratio of incorporation in ␣M2 (p ϭ 0.17).
Discussion
In these studies we examined the effects of tetracaine, PCP, and HTX on the pattern of photolabeling of [ 125 125 I (F, E) and picomoles of residues (Ⅺ, ‚) released during N-terminal sequencing of ␣-, ␤-, and ␦-subunit fragments isolated by SDS-PAGE and reversed phase HPLC from nAChRs photoincorporated with [ 125 I]TID in the absence (F, Ⅺ) and presence (E, ‚) of 50 M PCP. The data for the three subunits are from separate labeling experiments. For each subunit, the primary sequence detected began at the amino terminus of the M2 segment, and that sequence is shown at the top of each panel. No other sequences were detected at Ͼ10% of the primary sequence, except for the ␤-subunit control, which contained a secondary sequence beginning at ␤Lys-216 at the amino terminus of ␤M1 at onethird the level of the primary sequence. The initial (I 0 ) and repetitive (R) yields of for each sample as well as the efficiency of incorporation into M2-9 and M2-13 are listed in the Table 1B . Inset, 125 I release (E) for the ␤-subunit sample labeled in the presence of PCP plotted on an expanded scale. I (F, E) and picomoles of residues (Ⅺ, ‚) released during N-terminal sequencing of ␣-, ␤-, and ␦-subunit fragments isolated by SDS-PAGE and reversed phase HPLC from nAChRs photoincorporated with [ 125 I]TID in the absence (F, Ⅺ) and presence (E, ‚) of 30 M HTX. The controls for the ␣-and ␤-subunits are the same as in Fig.  6 , because for those subunits the labelings with PCP and HTX were carried out in parallel. For each subunit, the primary sequence detected began at the amino terminus of the M2 segment, and that sequence is shown at the top of each panel. No other sequences were detected at Ͼ10% of the primary sequence, except for the ␤-subunit control, which contained a secondary sequence beginning at ␤Lys-216 at the amino terminus of ␤M1 at one-third the level of the primary sequence. The initial (I 0 ) and repetitive (R) yields of sequencing as well as the efficiency of incorporation into M2-9 and M2-13 are listed in Table 1C . Insets, 125 I release (E) profiles for the samples labeled in the presence of PCP plotted on an expanded scale. mutually exclusive binding. The simplest interpretation of the data is that in the absence of agonist, PCP, or HTX binds at another site, presumably in the ion channel domain, and the binding results in a subtle shift of the orientation of [ 125 I]TID bound at M2-9/13. Tetracaine. In the analytical labeling experiments, high concentrations of tetracaine reduced [
125 I]TID photoincorporation into the nAChR ␥-subunit by 92 Ϯ 1% (Fig. 1) (White and Cohen, 1988; . However, tetracaine at concentrations up to 100 M does not desensitize the nAChR (Boyd and Cohen, 1984; Middleton et al., 1999) , and the IC 50 value of 3 M for tetracaine inhibition is consistent with its binding to the M2 ion channel domain in the absence of agonist. In our studies, nonradioactive TID reduced the equilibrium binding of [
